Median highlights AI lung cancer research

By staff writers

September 10, 2021 -- Median Technologies has released trial results showing that its artificial intelligence (AI) algorithm performed well in characterizing malignant and benign lung nodules in patients receiving low-dose chest CT lung cancer screening.

The company's new iBiopsy computer-aided diagnosis (CADx) algorithm was trained on a dataset from 1,224 patients with 11,392 nodules from the National Lung Screening Trial and then tested on CT images from 472 patients with 4,216 nodules. The application yielded 95.2% sensitivity and 95.7% specificity for lung nodule characterization, as well as an area under the curve of 0.991, Median said.

The company is planning an additional large-scale study for an end-to-end digital lung cancer screening application that will provide both nodule detection and characterization. Results are expected in the fourth quarter.

Copyright © 2021
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking